Northland Securities set a $5.00 price target on MOTIF BIO PLC/S (NASDAQ:MTFB) in a report released on Monday, TipRanks reports. The brokerage currently has a buy rating on the stock.
NASDAQ:MTFB traded down $0.05 during mid-day trading on Monday, reaching $0.66. The company’s stock had a trading volume of 70,577 shares, compared to its average volume of 105,923. MOTIF BIO PLC/S has a 1 year low of $0.60 and a 1 year high of $11.50. The business’s fifty day simple moving average is $1.01. The stock has a market capitalization of $10.54 million, a price-to-earnings ratio of -9.47 and a beta of 0.08.
A hedge fund recently bought a new stake in MOTIF BIO PLC/S stock. Virtu Financial LLC bought a new position in MOTIF BIO PLC/S (NASDAQ:MTFB) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 19,865 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned approximately 0.13% of MOTIF BIO PLC/S as of its most recent filing with the Securities and Exchange Commission (SEC). 7.58% of the stock is owned by institutional investors and hedge funds.
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
See Also: Insider Trading – What You Need to Know
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.